Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.46 |
| ▸ | CASP3 | P42574 | 2/20 | 0.44 |
| ▸ | EHMT2 | Q96KQ7 | 1/20 | 0.42 |
| ▸ | EHMT1 | Q9H9B1 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 2/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | GSK3B | P49841 | 1/20 | 0.37 |
| ▸ | CA12 | O43570 | 2/20 | 0.37 |
| ▸ | CA9 | Q16790 | 2/20 | 0.37 |
| ▸ | CA2 | P00918 | 1/20 | 0.37 |
| ▸ | TGM2 | P21980 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | GLS | O94925 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30124938 | 0.81 | ALDH1A1 (0.48) | ALDH1A1CASP3EHMT2EHMT1POLB | |
| SCHEMBL29372938 | 0.81 | ALDH1A1 (0.48) | ALDH1A1CASP3EHMT2EHMT1POLB | |
| SCHEMBL35297 | 0.81 | ALDH1A1 (0.48) | ALDH1A1CASP3EHMT2EHMT1POLB | |
| SCHEMBL4905639 | 0.78 | ALDH1A1 (0.43) | ALDH1A1CASP3EHMT2EHMT1POLB | |
| SCHEMBL20954062 | 0.75 | POLB (0.46) | ALDH1A1CASP3EHMT2EHMT1POLB | |
| SCHEMBL14050320 | 0.74 | ALDH1A1 (0.43) | ALDH1A1CASP3EHMT2EHMT1POLB | |
| SCHEMBL238005 | 0.73 | POLB (0.44) | ALDH1A1CASP3EHMT2EHMT1POLB | |
| SCHEMBL30996374 | 0.73 | POLB (0.44) | ALDH1A1CASP3EHMT2EHMT1POLB | |
| SCHEMBL23604158 | 0.71 | POLB (0.43) | ALDH1A1CASP3EHMT2EHMT1POLB | |
| SCHEMBL1553885 | 0.71 | CASP3 (0.46) | ALDH1A1CASP3EHMT2EHMT1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060286626-A1 | Selective chromophores | WESTMAN GUNNAR | 2006-12-21 | — | — | US | claimed |
| EP-1509508-A1 | SELECTIVE CHROMOPHORES | Westman, Gunnar (SE) | 2005-03-02 | — | — | EP | claimed |
| WO-2003104210-A1 | SELECTIVE CHROMOPHORES | CHALMERS TECHNOLOGY LICENSING AB (SE) | 2003-12-18 | — | — | WO | claimed |
| EP-0566157-A1 | Neutral metalloendopeptidase inhibitors in the treatment of hypertension | SCHERING CORPORATION (US) | 1993-10-20 | — | — | EP | claimed |
| US-4808713-A | Anthypertensive pyridazo [1,2-a][1,2]diazepines | HOFFMAN-LA ROCHE INC. (US) | 1989-02-28 | — | — | US | claimed |
| US-4772701-A | Pyridazo[1,2]pyridazines and pyrazolo[1,2]pyridazines as antihypertensives | HOFFMANN-LA ROCHE INC. (US) | 1988-09-20 | — | — | US | claimed |
| US-4749688-A | Use of neutral metalloendopeptidase inhibitors in the treatment of hypertension | SCHERING CORPORATION (US) | 1988-06-07 | — | — | US | claimed |
| EP-0254032-A2 | Neutral metalloendopeptidase inhibitors in the treatment of hypertension | SCHERING CORPORATION (US) | 1988-01-27 | — | — | EP | claimed |
| US-4658024-A | Pyrazolo [1,2-a][1,2]-diazepines useful as antihypertensives | HOFFMANN-LA ROCHE INC. (US) | 1987-04-14 | — | — | US | claimed |
| US-4512924-A | HYPOTENSIVE AGENTS | HOFFMANN-LA ROCHE INC. (US) | 1985-04-23 | — | — | US | claimed |
| US-7244847-B2 | Benzimidazole compounds | ISIS PHARMACEUTICALS, INC. (US) | 2007-07-17 | — | — | US | disclosed |
| US-20060286626-A1 | Selective chromophores | WESTMAN GUNNAR | 2006-12-21 | — | — | US | disclosed |
| US-20050272649-A1 | Conjoint administration of morphogens and ACE inhibitors in treatment of chronic renal failure | STRYKER CORPORATION | 2005-12-08 | — | — | US | disclosed |
| EP-1578360-A2 | CONJOINT ADMINISTRATION OF MORPHOGENS AND ACE INHIBITORS IN TREATMENT OF CHRONIC RENAL FAILURE | Curis, Inc. (US) | 2005-09-28 | — | — | EP | disclosed |
| EP-1509508-A1 | SELECTIVE CHROMOPHORES | Westman, Gunnar (SE) | 2005-03-02 | — | — | EP | disclosed |
| US-4512924-A | HYPOTENSIVE AGENTS | HOFFMANN-LA ROCHE INC. (US) | 1985-04-23 | — | — | US | disclosed |
| EP-0131314-A1 | Reactive monoazo dyestuffs | MITSUBISHI KASEI CORPORATION (JP) | 1985-01-16 | — | — | EP | disclosed |
| US-4229456-A | SUPPRESSION OF GASTRIC SECRETIONS | MERCK & CO., INC. (US) | 1980-10-21 | — | — | US | disclosed |
| EP-0000490-A1 | Substituted naphthyridinones, processes for their preparations and therapeutical applications | MERCK & CO. INC. (US) | 1979-02-07 | — | — | EP | disclosed |
| US-4133885-A | GASTRIC SECRETIONS INHIBITORS | MERCK & CO., INC. (US) | 1979-01-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060286626-A1 | Selective chromophores | MKI67, TUBB6, BOD1L1 | ALDH1A1 530/4885CASP3 994/4885EHMT2 4364/4885 |
| US-20050272649-A1 | Conjoint administration of morphogens and ACE inhibitors in treatment of chronic renal failure | BMPR2, BMP2, BMP1 | ALDH1A1 1747/4885CASP3 1459/4885EHMT2 2869/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.